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Abstract
The identification of nucleotide sequence variations in viral pathogens linked to disease and clinical outcomes is important
for developing vaccines and therapies. However, identifying these genetic variations in rapidly evolving pathogens adapting
to selection pressures unique to each host presents several challenges. Machine learning tools provide new opportunities to
address these challenges. In HIV infection, virus replicating within the brain causes HIV-associated dementia (HAD) and
milder forms of neurocognitive impairment in 20–30% of patients with unsuppressed viremia. HIV neurotropism is primarily
determined by the viral envelope (env) gene. To identify amino acid signatures in the HIV env gene predictive of HAD, we
developed a machine learning pipeline using the PART rule-learning algorithm and C4.5 decision tree inducer to train a
classifier on a meta-dataset (n=860 env sequences from 78 patients: 40 HAD, 38 non-HAD). To increase the flexibility and
biological relevance of our analysis, we included 4 numeric factors describing amino acid hydrophobicity, polarity, bulkiness,
and charge, in addition to amino acid identities. The classifier had 75% predictive accuracy in leave-one-out cross-validation,
and identified 5 signatures associated with HAD diagnosis (p,0.05, Fisher’s exact test). These HAD signatures were found in
the majority of brain sequences from 8 of 10 HAD patients from an independent cohort. Additionally, 2 HAD signatures
were validated against env sequences from CSF of a second independent cohort. This analysis provides insight into viral
genetic determinants associated with HAD, and develops novel methods for applying machine learning tools to analyze the
genetics of rapidly evolving pathogens.
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Introduction
The identification of nucleotide sequence variations in viral
pathogens linked to disease and clinical outcomes is important for
developing treatments and vaccines, and furthering our under-
standing of host-pathogen interactions. However, identifying viral
mutations correlated to disease phenotype requires addressing a
number of challenges, including high viral mutation rates and
rapid evolution of viral pathogens in response to host selection
pressures. Rapidly evolving viral pathogens, such as HIV, hepatitis
C, and influenza, adapt to immune and drug selection pressures
unique to each host as well as unique microenvironments within
individual tissue sites [1–6]. Additionally, viral populations within
a host often share phylogenetic lineages due to founder effects and
genetic bottlenecks arising from primary infection by a small viral
population [1,7,8]. Amino acid sequences exist within the three-
dimensional structure of a folded protein, bringing distant regions
in close proximity and increasing the likelihood of compensatory
mutations and genetic covariation between non-contiguous amino
acid positions [9]. Moreover, in some instances similar amino
acids can fulfill similar biochemical roles within a protein, making
them functionally interchangeable [10,11]. Because of these
properties, biologically relevant signatures have the potential to
include sets of amino acids with similar biochemical properties at
positions distant in the linear sequence. Addressing these
challenges requires statistical methods able to mine complicated
datasets and discriminate between relevant genetic signatures and
patient-specific adaptations.
Recent works have applied machine learning tools to discover
patterns in noisy biological datasets [12–14]. For example,
classifier-based machine learning methods trained on HIV
sequences can accurately predict biologically relevant outcomes
such as coreceptor usage, immune epitopes, and drug resistance
mutations, and identify functional groupings of amino acid
positions within protein classes [11,15,16]. However, many of
these works focus on development of a tool for classification of
novel sequences, and thus utilize machine-learning algorithms,
such as SVM, whose resulting classifiers are not easily interpret-
able [17]. Pillai et al. applied the more interpretable C4.5 and
PART algorithms to investigate amino acid positions discriminat-
ing HIV coreceptor usage or tissue compartment of origin
[4,16,18], though the positions identified were not used to
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outcome. Further studies have identified genetically linked amino
acid positions in the HIV env by utilizing mutual information
analysis and evolutionary-network modeling [19–21]; however,
correlation to clinical outcome was not explored. Recent work
identified HIV env signatures found in early infection, but this
analysis assessed participation in a priori defined structural and
functional groups [22]. Current machine learning algorithms can
train a naı ¨ve classifier to identify genetic signatures correlated with
clinical outcome with no requirement for initial structural or
functional information. However, careful algorithm selection and
dataset assembly is required to allow interpretation of the resulting
classifier.
The genetic diversity and high mutation and replication rate of
HIV create significant opportunities and challenges for sequence
analysis [23]. As well as being the causative agent in AIDS, HIV
replicating in the brain is linked to development of HIV-associated
neurological disorders (HAND) of which the most serious, HIV-
associated dementia (HAD), occurs in 20–30% of untreated
patients [24,25]. Highly active antiretroviral therapy (HAART)
has reduced the incidence of HAD, but the prevalence of less
severe neurocognitive disorders has increased significantly [26–
34]. Furthermore, in settings where access to antiretroviral
treatment is limited, HAD remains a significant cause of mortality
and morbidity [24].
The mechanisms leading to the development of HAD are not
well understood (reviewed in [24,32,34,35]). HIV enters the brain
early in acute infection, likely via trafficking of infected lympho-
cytes and monocytes [36–39]. HIV replicates in CD4+ T-cells and
macrophages in non-brain tissues and predominantly in macro-
phages and microglia within the brain [24,40–42]. Neuronal
injury may begin during the burst of viral replication occurring in
the acute phase soon after infection, and may continue during
chronic replication of virus in the brain throughout infection
[24,30]. However, the presence of virus replicating in the brain
alone is not sufficient to induce neuronal damage; only a subset of
patients develop neurocognitive impairment and there is disagree-
ment over whether high levels of viral replication in the blood,
CSF, or brain are predictive for development of HAD (reviewed in
[24,32]). Nadir CD4 count and baseline plasma or CSF viral load
are associated with increased risk of neurocognitive impairment in
treatment-naı ¨ve patients; however, these relationships are con-
founded by HAART treatment and tissue site variations in viral
load [27,43–50]. A better understanding of mechanisms underly-
ing development of HAD is required for improved diagnosis,
treatment, and prevention.
The HIV env gene is the main viral determinant of macrophage
tropism and viral replication in the brain, and has also been
implicated in viral neurotoxicity [24,38,51–57]. Potential causes of
neurotoxicity include direct effects, including env binding and
activation of chemokine receptors, or bystander effects, such as
immune activation and inflammation [24,35,58–61]. Viral entry
into the brain is thought to be ubiquitous across patients; however,
levels of viral entry and replication in the brain vary from
undetectable to high, as do degrees of neurocognitive impairment,
though not necessarily in tandem [34,45,46,49,62–64]. Previous
work demonstrated a close relationship between macrophage
tropism and brain compartmentalization [65–69], and identified
amino acid positions in env associated with replication in brain or
development of HAD [18,56,70–75]; however, these findings are
not sufficient to explain the observed clinical variability, nor do
they address combined effects of multiple amino acid positions. To
identify genetic signatures in the HIV env gene associated with
HAD, we developed a machine-learning pipeline capable of
mining genetic sequences to identify sets of amino acids correlated
to clinical outcome. We then applied this pipeline to the analysis of
a meta-dataset of HIV env sequence sampled from the brain of 78
patients clinically assessed for the development of HAD.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The IRB at Dana-Farber Cancer
Institute approved the research as exempt because all data and
samples were obtained anonymously without any donor identities.
Assembly of Training and Validation Meta-datasets
We utilized the HIV Brain Sequence Database [76,77] to
assemble a training meta-dataset of 860 clade-B HIV env sequences
cloned directly from the brain of 78 patients without prior
coculture or in vitro passage (Table 1). Clinical diagnoses of HIV-
associated neurological disorders were obtained for all patients,
either from the database or their original publications. In most
cases diagnoses correspond to guidelines established by the
Working Group of the American Academy of Neurology AIDS
Task Force [78] and updated by the National Institute of Mental
Health and the National Institute of Neurological Diseases and
Stroke Working Group [25]. For each patient, genetic compart-
mentalization was assessed using the Slatkin-Maddison test [79],
implemented in Hyphy [80], to make pairwise comparisons
between tissue compartments with greater than 20 sequences in at
least one compartment and greater than 4 sequences in both, as
indicated by previous work benchmarking compartmentalization
analysis [81].
Generation of Phylogenetic Tree
An amino acid consensus sequence was generated for each
patient using the consensus maker tool at the LANL HIV
Sequence Databases [82]. Consensus sequences were used to
generate a phylogenetic tree by maximum likelihood in the
Treefinder program [83] using the JTT substitution matrix, and
an optimized discrete Gamma heterogeneity model with 4 rate
classes.
Alignment, Weighting, and Translation of Sequences to
Amino Acid Properties
Sequences were aligned and translated to amino acids using the
HIVAlign tool from the LANL HIV Databases [82] implementing
HMM-align [84], and the resulting alignments manually adjusted.
Shannon entropy of the amino acid alignment was calculated
using the Entropy-One tool hosted at the LANL HIV Sequence
Databases [82]. To ensure that patients with different sequencing
depth were weighted equally, individual sequences were weighted
by: (total number of sequences in the dataset)/(total number of
patients * total sequences in that patient) as described previously
[85].
Four numeric factors describing amino acid biochemical
properties were added to the alignment, in addition to amino
acid identities, representing each amino acid position in each
sequence as a categorical identity plus a vector of 4 numeric
factors. These factors, representing amino acid polarity, secondary
structure, molecular size or volume, and electrostatic charge, were
derived in work by Atchley et. al. [10] by applying factor analysis
to the 494 attributes in the AAIndex [86]. The resulting
alignments of amino acid identities and factors were converted
to ARFF format using a custom perl script.
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in Weka
Weka version 3.7.3 was used as a data mining platform and
included the J48 implementation of the C4.5 decision tree inducer
[87]. Feature selection was performed using the WrapperSubse-
tEval method and J48 decision tree inducer both with default
parameters for feature evaluation, and the BestFirst greedy hill-
climbing algorithm for optimal feature search. For the selected
features, the PART rule-learning algorithm [88] utilizing the J48
decision tree inducer was applied with default parameters to
classify sequences by HAD diagnosis. Individual rules within the
rule-set were interpreted as amino acid signatures. Rules based on
numeric ranges of amino acid factors were converted to lists of
matching amino acids. Accordingly, ranges of biochemical
features derived by machine learning may include amino acid
identities not actually observed at that position in the training
dataset. Therefore, only those amino acids actually observed at
that position within the training dataset are included in the
signature. After signature generation, all amino acid positions
included in signatures were removed from the original dataset and
the feature selection and PART steps were iterated. Iterative
signature generation continued until signatures gave no improve-
ment over random class assignment as assessed by the kappa
statistic ,=0, calculated using a multi-instance learning wrapper
to account for grouping of sequences by patient.
Validation
Leave-one-out cross validation was performed using a custom
perl script, sequentially holding out one patient from the training
set, retraining the classifier, and evaluating its ability to predict the
class of the held out patient. Optimal patient classification was
achieved using HAD signatures only. Patients were classified as
HAD when 95% of their constituent sequences matched a HAD
signature.
Fisher’s exact test was used to assess the distribution of HAD
and non-HAD patients with sequences matching each signature.
Q-values were calculated from p-values using fdrtool {Untitled:tn}
in R.
Results
A Machine Learning Pipeline for Genetic Analysis
To develop an exploratory tool that would allow identification
of HIV genetic signatures correlated to HAD, we developed a
machine-learning pipeline utilizing the C4.5 decision tree inducer
incorporated in the PART algorithm to analyze a meta-dataset of
env sequences. A similar method utilizing the PART algorithm
with cross-validation was previously used to predict coreceptor
usage of HIV env sequences, resulting in greater predictive
accuracy than the ‘‘charge rule’’ [16].
Decision tree induction and specifically the C4.5 algorithm is a
powerful method of training an interpretable classifier that
identifies sets of attributes able to differentiate between classes of
observations. The algorithm has the advantage of functioning well
within a noisy dataset and incorporates methods of accounting for
missing data, an important factor as differing sequencing coverage
leads to incomplete data at borders of the region analyzed. The
C4.5 algorithm trains a decision tree by sequentially adding
attributes that best differentiate between class, then pruning the
resulting tree to control for overfitting. The resulting decision tree
is readily interpretable, allowing identification of sets of attributes
most discriminatory for class. To translate decision trees into
independent sets of genetic signatures, we adopted the PART
algorithm, based on C4.5, to generate decision rule sets. Briefly,
the PART algorithm uses C4.5 to generate a decision tree, and
Table 1. Summary of patients included in the brain training, brain validation, and CSF validation HIV env sequence datasets.
HAD non-HAD All
A Brain training set
Publications 18
Patients 40 38 78
Sequences 604 256 860
Median CD4
a: count (range) 40 (2–400) 246 (0–824) 87 (0–824)
ART Treatment
b ART: 18, none: 2, unknown: 13 ART: 8, none: 16, unknown: 14 ART: 26, none: 2, unknown: 27
B Brain test set
Publications 3
Patients 10 0 10
Sequences 75 0 75
Median CD4
a: count (range) 60 (77–120) 60 (77–120)
ART Treatment
b ART: 3, none: 1, unknown: 6 ART: 3, none: 1, unknown: 6
C CSF
Publications 7
Patients 27 14 41
Sequences 277 116 393
Median CD4
a: count (range) 137 (16–592) 200 (13–512) 146.5 (13–592)
ART Treatment
b ART: 20, none: 3, unknown: 4 ART: 5, none: 2, unknown: 7 ART: 25, none: 5, unknown: 11
Patient annotations and publication references available in Table S1.
aCells per microliter.
bART, antiretroviral therapy.
doi:10.1371/journal.pone.0049538.t001
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leaf as a rule set predictive of the class of that leaf. All sequences
matching that rule are removed from the analysis, and the process
is iterated to generate a new rule until all sequences can be
classified. The PART algorithm has the advantage of generating
sets of independent rules linked to class, each of which can be
interpreted as an amino acid signature correlated to patient
diagnosis. Using feature selection to reduce the number of
attributes supplied to a machine-learning algorithm has been
shown to improve performance [89]. Therefore, prior to rule
generation using the PART algorithm, we used a wrapper method
with the C4.5 decision tree inducer evaluated by a greedy hill-
climbing algorithm to select the optimal set of attributes for
machine learning. Because the PART algorithm generates an
optimal classifier, not necessarily a classifier that captures the
entirety of the structure within the data, we recursively applied
PART, removing amino acid positions incorporated into signa-
tures after each iteration, until the resulting classifier showed no
improvement over random assortment by kappa statistic. The
kappa statistic measures the chance-corrected agreement between
the classifier and true classes; a kappa statistic greater than zero
indicates better than random assortment and a kappa of one
indicates perfect agreement [90]. The complete analysis pipeline is
illustrated in Figure 1.
Meta-dataset Assembly
One challenge to examining the viral genetics associated with
development of HAD is assembling a dataset of brain-derived viral
sequences containing a sufficient sample size of patients and
sequences to provide statistical power for data analysis. The
majority of brain tissue samples are obtained at autopsy, and few
studies have assembled a large cohort of HIV patients and
samples. To address this, we used the HIV Brain Sequence
Database (HBSD) to assemble a meta-dataset containing published
clade B HIV env sequences cloned from brain tissue [76,77]. The
HBSD is a curated database of HIV env sequences cloned directly
from tissues, using methods that minimize the chance of PCR
resampling. Previous work sequencing brain-derived env sequences
has focused mainly on the V3 region, which contains important
determinants of viral coreceptor usage, macrophage and brain
tropism, and influences interactions with chemokine receptors,
which in turn may influence neuroinflammation and neurotoxicity
[24,35,52,61,91–93]. We focused on the V3 loop and surrounding
C2 and C3 regions, amino acid positions 265–369 (numbered
according to the reference strain HXB2, Genbank accession
number K03455), both because of its biological importance and
because this region provided the greatest number of patients and
sequence depth. The meta-dataset contains 860 sequences from 78
patients (40 HAD and 38 non-HAD) (Table 1 and Table S1A).
The majority of patients (n=63) were sampled at autopsy with
late-stage AIDS and low CD4 counts (median CD4 T cell count
was 87 cells/mL); however, this dataset also included 15 patients
Figure 1. Analysis pipeline for identification and validation of genetic signatures associated with HAD. After initial assembly,
alignment, and weighting of the sequence dataset, for each amino acid position in each sequence, four numeric factors describing the biochemical
properties of the amino acid at that position are added to the alignment. This factor alignment enters the machine-learning phase where preliminary
feature selection is used to select the attributes (amino acid identities or biochemical factors) that best differentiate between classes. Using the PART
algorithm, this reduced set of attributes is used to train decision rules describing amino acid signatures correlated to disease outcome. Amino acid
positions included in these signatures are removed from the main factor alignment and the process is iterated until no additional discriminatory
signatures can be generated. Signatures are then validated by leave-one-out cross-validation, Fisher’s exact test, and assessment in brain and CSF-
derived virus from independent cohorts.
doi:10.1371/journal.pone.0049538.g001
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related causes. The majority were sampled between 1991 and
2000, and were drug naive or on pre-HAART regimens. For all
patients with sufficient sequences from brain and non-brain tissue
sites for phylogenetic testing of compartmentalization (38 of 78
patients), brain-derived sequences were genetically compartmen-
talized from non-brain sequences (p,0.05 by Slatkin-Maddison
test for compartmentalization). Patients were clinically assessed for
dementia status and grouped either as HAD, which included
diagnoses of mild, moderate, or severe HAD and severity not
specified, or non-HAD, which included patients that were
clinically assessed and determined to be non-demented. Removing
mild-HAD patients from the analysis, including only severe-HAD
patients, or removing presymptomatic patients, produced similar
results to analysis of the full dataset, albeit at lower statistical power
due to reduced patient numbers (data not shown).
Within the meta-dataset, patient depth of sequencing was
variable, ranging from patients with a single sequence to patients
with 116 sequences. Median sequencing depth was 5, and was
similar between HAD and non-HAD (5.5 and 5, respectively).
Virus within each patient is genetically related due to founder
effects caused by infection by a small initial population.
Unaddressed, this has the potential to bias analysis for motifs
found in highly sequenced patients. To account for this effect, we
weighted sequences by the inverse of patient sequencing depth,
such that all patients had equal weight during data mining, as
described previously [85].
To rule out patient clustering by study or tissue bank, or
transmission chains, we constructed a phylogenetic tree of the
amino acid consensus sequences for the C2-V3-C3 region of each
patient (Figure 2). We observed no patient clustering by study or
tissue bank. Additionally, we observed no clustering by dementia
status; HAD (red) and non-HAD (blue) patients were interspersed
throughout the branches of the tree.
Addition of Biochemical Factors to the Amino Acid
Alignment
A preliminary analysis of the amino acid alignment identified
positions where multiple amino acid identities were correlated to
one class of disease outcome. Sets of amino acids can have similar
biochemical properties and may fulfill the same functional role in a
protein. To increase the flexibility and power of the analysis, we
incorporated numeric measures of amino acid biochemical
properties into the analysis. We utilized the work of Atchley et al.
[10], which applied factor analysis to summarize the contents of
the Amino Acid Index, a comprehensive but highly redundant
database of 494 numeric descriptors of amino acid biochemical
properties, into 5 global factors: Factor 1: Polarity, Accessibility,
Hydrophobicity; Factor 2: Propensity for Secondary Structure;
Factor 3: Molecular Size; Factor 4: Codon Composition; Factor 5:
Electrostatic Charge. These factors are linear and numeric,
Figure 2. Unrooted phylogenetic tree of patient consensus sequences for the C2-V3-C3 region of HIV env. A consensus sequence for
the C2-V3-C3 region was generated for each patient in the brain dataset (n=78). These consensus sequences were used to generate an unrooted
maximum likelihood tree. Patients are colored by HAD diagnosis and identified by patient codes taken from their original publication.
doi:10.1371/journal.pone.0049538.g002
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chose to include 4 of the 5 factors describing basic amino acid
biochemical properties, excluding codon composition, as we were
most interested in mining functional roles of amino acids within
env. Our final dataset consisted of an amino acid alignment for
which each position in each sequence consisted of a categorical
attribute for amino acid identity and 4 numeric attributes
describing properties of that amino acid. Analysis of identities
plus 4 amino acid factors showed improvement in the descriptive
power of resulting signatures over analysis of identities alone. At
positions where multiple amino acids were correlated with class,
mining identities alone resulted in generation of redundant
signatures differing only at one position (data not shown). In
contrast, the addition of numeric factors describing biochemical
properties allowed generation of single signatures that included a
numeric range encompassing correlated amino acids.
Generation and Validation of Amino Acid Signatures
Analysis of the training dataset of amino acid identities and 4
biochemical factors completed 2 iterations of the data-mining
pipeline, generating kappa statistics of 0.332 and 0.28. The
pipeline stopped after the second iteration, discarding the third set
of signatures with a kappa statistic of -0.14, indicating no
improvement over random assortment. These first 2 iterations
produced sets of 8 and 10 signatures, respectively. A negative
control set was generated by randomly permuting HAD diagnosis
class labels across patients. The data mining pipeline identified no
predictive signature sets from the negative control set and stopped
in the first iteration with a kappa value of 20.041 (data not
shown). We retained the rules generated from this negative control
for use in further validations. Because our dataset was not of
sufficient size to split into training and test sets, we used leave-one-
out cross validation to determine predictive accuracy and test for
overfitting. This method generates a series of independent training
and test sets by sequentially removing one patient from the
training set, retraining the classifier and testing the ability of the
classifier to predict the HAD status of the held-out patient. We
examined the distribution of HAD and non-HAD classified
sequences within patients to select criteria for patient classification.
For the majority of patients, the percentage of sequences matching
a signature was close to a binary division; either no sequence
matched or all or nearly all sequences matched. HAD signatures
were a stronger predictor of patient class than non-HAD
signatures, and the most accurate predictions were made based
on HAD signatures alone. This led us to empirically set the
threshold for classifying a patient as HAD at 95% of the patient’s
sequences predicted as HAD, yielding a 75% predictive accuracy
in leave-one-out cross validation.
To assess the associations of individual signatures with patient
class, we used Fisher’s exact test to evaluate the distribution of
matching sequences across patients. The PART algorithm utilizes
a layered approach to mine sub-structures within the data,
removing matching sequences before training the next signature.
However, we wished to determine which signatures were
independently significant, outside the background of preceding
signatures. Thus, we evaluated the distribution of matching
sequences across patients in the complete brain dataset. 5 of 8
signatures in the first iteration and 5 of 10 signatures in the second
iteration had p-values ,0.05 (Table 2). Of these 10 signatures, 5
were associated with HAD and 5 with non-HAD. False discovery
rate-adjusted q-values were significant (q,0.05) for each of these
10 signatures (data not shown).
One caveat to the analysis by Fisher’s exact test is that the p-
values generated resulted from testing the frequency of these
signatures in the same dataset from which they were generated. To
examine this bias, we applied Fisher’s exact test to the set of
negative control signatures generated in the first iteration (kappa
value 20.041) of the patient class-permuted negative control
Table 2. Statistical validation against patients in the brain HIV
envsequence dataset of all HAD and non-HAD signatures
generated by the PART algorithm.
Signature Diagnosis Patient Count:
Matching
Patients: p-value
Total (HAD/None)HAD non-HAD
1_01 * HAD 77 (39/38) 10 0 1.0E-03
1_02 * non-HAD 77 (39/38) 1 9 6.8E-03
1_03 * non-HAD 77 (39/38) 2 8 0.047
1_04 * HAD 77 (39/38) 18 1 7.5E-06
1_05 non-HAD 77 (39/38) 7 12 0.19
1_06 non-HAD 51 (31/20) 11 5 0.54
1_07 * non-HAD 77 (39/38) 9 23 1.2E-03
1_08 HAD 77 (39/38) 34 33 1
2_01 * HAD 77 (39/38) 9 1 0.014
2_02 * non-HAD 76 (38/38) 0 9 2.3E-03
2_03 * HAD 77 (39/38) 14 2 1.4E-03
2_04 * non-HAD 70 (33/37) 9 20 0.030
2_05 * HAD 76 (38/38) 25 4 1.0E-06
2_06 non-HAD 49 (30/19) 13 8 1
2_07 non-HAD 77 (39/38) 4 8 0.22
2_08 non-HAD 77 (39/38) 18 16 0.82
2_09 HAD 77 (39/38) 12 5 0.098
2_10 non-HAD 77 (39/38) 23 25 0.64
The statistical significance of all HAD and non-HAD signatures was determined
using Fisher’s exact test to evaluate the distribution of patients in the brain
dataset with matching sequences. Diagnosis indicates whether the signature
was predictive of HAD or non-HAD. Patient count reflects the total number of
patients with sequence spanning the amino acid positions in the relevant
signature (i.e. signature 1_01 was tested in 77 patients because 1 patient does
not contain sequences spanning positions 304 through 343, which are included
in signature 1_01). The number of HAD and non-HAD patients from the brain
dataset, containing sequences matching each signature are given, followed by
the p-value of that patient distribution, calculated by Fisher’s exact test.
*=p-value ,0.05.
doi:10.1371/journal.pone.0049538.t002
Figure 3. Amino acid positions identified in each HAD
signature. Amino acid positions are plotted for each HAD signature
against a schematic of the HIV C2-V3-C3 region examined. Shannon
entropy values of all positions in the alignment are plotted as a bar
graph, with colored bars marking positions included in HAD signatures.
doi:10.1371/journal.pone.0049538.g003
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,0.05 (data not shown), indicating that the significant p-values we
observed are unlikely due to applying Fisher’s exact test against
our training dataset.
Figure 4. Amino acid identity and biochemical factor require-
ments for HAD signatures. Amino acid requirements at each
position are plotted. For each ‘‘position: factor’’ pair, all amino acids are
plotted at their value for that factor. Amino acids observed at that
position within the brain-derived dataset are plotted in black, while
those not observed are gray. The B-clade consensus amino acid is
plotted in large font. The colored bar indicates the range of acceptable
values in that signature. Lower range ends are open, indicated by a
dotted line, (signature 1_01, position 328 excludes Q). Upper range
ends are closed, indicated by a solid line (signature 2_03, position 321
includes S).
doi:10.1371/journal.pone.0049538.g004
Figure 5. Amino acid distributions at individual positions are
not correlated with HAD. A. Amino acid frequencies in the brain
dataset plotted as distributions totaling 100% for each class (HAD, non-
HAD). The weights of individual sequences are normalized by patient
sequencing depth. B. Percentage of sequences of each class (HAD, non-
HAD) matching the amino acid requirements of signature 1_04 at each
position individually, and for the complete signature. Bars represent
only matching sequences and thus do not sum to 100%.
doi:10.1371/journal.pone.0049538.g005
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HAD signatures alone were the best predictor of patient class, we
focused further analysis on the 5 HAD signatures that showed
significant association with HAD diagnosis by Fisher’s exact test.
Most of these signatures consisted of amino positions in the tip of
the V3 loop and pairs of positions, approximately equidistant on
either side of the tip of the V3 loop, spanning the C2-V3-C3
region (Figure 3). Shannon entropy was calculated for amino acid
positions across the region analyzed. Signatures included both
high and low entropy positions, demonstrating no clear bias by
entropy. Examining the rules comprising each signature revealed
that the amino acid requirements could consist of a combination of
single amino acid identities, groups of amino acids, and larger
amino acid sets (Figure 4 and Figure S1). Given the amino acids
observed within the dataset, many of these larger amino acid sets
effectively exclude a single amino acid. For example, within
Figure 6. Proportion of sequences per patient from the brain dataset matching HAD signatures. For each HAD signature, HAD (red) and
non-HAD (blue) patients are plotted according to their total number of sequences (x-axis) and the number of sequences matching the signature (y-
axis). Patients with no matching sequences are omitted from the plot for clarity, but are included for statistical calculations. Dashed line indicates
slope=1 at which all sequences in a patient match signature. Jitter has been added to visualize overlapping points. Text indicates p-value by Fisher’s
exact test and the number of patients from each class with matching sequences.
doi:10.1371/journal.pone.0049538.g006
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based on size, which can be interpreted as a ‘‘not-Q’’ requirement.
Unexpectedly, the amino acid distributions at individual positions
did not demonstrate significant bias by HAD diagnosis (Figure 5).
For example, the individual positions comprising signature 1_04
(290, 315, and 343) show only minor amino acid bias between
HAD and non-HAD patients. Additionally, at each position the
sets of amino acids from signature 1_04 show only a minor bias
between HAD and non-HAD patients. KER at position 343 shows
no significant bias and E at position 290 and SKAG at position
315 each have a p-value ,0.05, but are not strongly associated
with HAD. Instead, these positions only correlated to HAD
diagnosis when combined into the overall signature.
To better understand the distribution of each signature within
patients, we visualized the proportion of sequences in each patient
matching each of the significant HAD signatures (Figure 6 and
Figure S2). Patients with no matches were omitted from the
visualization for clarity, but were included in the statistical analysis
with Fisher’s exact test. Signatures had a strong bias to uniquely
match sequences derived from either HAD patients (Figure 6) or
non-HAD patients (Figure S2). In addition to being highly
discriminatory for patient class, matching sequences appear to
have expanded nearly to fixation within patients. For most patients
with sequences matching a signature, all or nearly all sequences
were matching. Depth of patient sequencing seemed to have little
effect on the likelihood of patient matches to a signature. In most
cases, the proportion of matching sequences remained similar
across patients with differing sequencing depth.
Sets of signatures can contain unique or overlapping amino acid
positions and requirements, raising the possibility of individual
sequences matching multiple signatures. To examine the propen-
sity of sequences to match multiple signatures, we visualized
individual sequences across all signatures (Figure 7). Several
sequences matched 3 signatures; however, most sequences
matched two or fewer signatures.
Evaluation of Signatures in Two Independent Non-brain
Datasets
To assess these signatures in HIV env sequences from an
independent cohort of patients, we assembled two validation
datasets. The first consisted of virus sampled from the brain of 10
independent HAD patients (Table 1B and Table S1B). This
dataset allowed us to empirically observe the occurrence of HAD
signatures in sequences from the brain of an independent cohort,
albeit one of insufficient sample size for statistical assessment, and
containing only HAD patients (Figure 8). For most patients in this
set, the majority or all sequences matched a HAD signature. For
patient 7766, all 25 sequences matched signatures 2_01 and 2_05.
All sequences from patients 47, 55 and 60 matched signatures
1_01, 2_05 and 2_03, respectively, though each of these patients is
represented by only 1 or 2 sequences. Finally, the majority of
sequences from patients E21, 6568 and CA110 matched
signatures 1_04 and 2_05. Thus, 8 of 10 HAD patients from an
independent cohort had 50% or greater sequences matching a
HAD signature.
The second validation set consisted of virus sampled from the
CSF of patients clinically assessed for HAD diagnosis. In this case,
we utilized CSF-derived virus as a surrogate for virus replicating in
the brain, based on phylogenetic evidence that brain and CSF-
derived virus are more closely related to each other than to non-
CNS tissue sites [6]. The CSF-derived validation dataset consisted
of 393 HIV env sequences cloned from the CSF of an independent
cohort of 41 patients (Table 1 and Table S1C). 30 patients had
reported CD4 T cell counts (median 147 cells/mL; range, 13–592),
of which 23 had advanced disease (defined as current or nadir
CD4 count ,200). Patient CD4 counts, AIDS progression, and
treatment histories were matched as closely as possible to patients
in the brain-derived dataset and all virus was clade-B. HIV in the
CSF can originate either from the brain or from blood and
lymphoid tissues. Early in infection, virus in the CSF appears
predominately blood and lymphoid-derived [94]; during late
infection, phylogenetic analysis demonstrates that CSF virus is
more closely related to virus replicating in the brain [69,73,95]. To
increase the probability that the validation dataset was more likely
brain-derived, we included only patients for which CSF-derived
virus was genetically compartmentalized from virus sampled from
non-CNS sites as determined by the Slatkin-Maddison test
(p,0.05). Testing significant HAD signatures identified from the
brain-derived dataset against sequences from the CSF demon-
strated that HAD signatures 1_04 and 2_03 were predominantly
matched by CSF virus from HAD patients (Figure 9A). Signature
1_04 matched 7 HAD and 2 non-HAD patients, and signature
2_03 matched 5 HAD and 1 non-HAD patient (Figure 8B),
however, because of the small and unequally distributed number
of patients in this dataset, these distributions did not reach
statistical significance. Additionally, between brain and CSF
derived datasets, sequences matching these signatures had similar
diversities of amino acids (Figure 8C). Signature 1_04 requires
ASK or G at position 315, matching sequence from the brain
contains ASK and G, and matching sequence from the CSF
contains AS and K.
Discussion
Here we developed a method of applying machine learning
tools to identify genetic signatures in viral pathogen genomes
correlated to disease outcome, in this case the development of
HIV-associated dementia. Our method expands the flexibility and
biological relevance of the analysis by including numeric factors
Figure 7. Distribution of matching sequences across HAD signatures. Visualization of sequences (x-axis) matching HAD signatures (y-axis).
Colored bars on top of the x-axis indicate HAD (red) or non-HAD (blue) diagnosis of the patient from which the sequence was sampled. Sequences
are clustered by their pattern of signature matches.
doi:10.1371/journal.pone.0049538.g007
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method to the C2-V3-C3 region of the HIV env gene and
identified 5 HAD signatures correlated to the presence of
dementia. We evaluated these signatures in two independent
datasets, and observed HAD signatures in the majority of brain-
derived env sequences from 8 of 10 patients with dementia, and
validated 2 signatures in HIV env sampled from the CSF. This
work demonstrates that our machine-learning pipeline can identify
biologically relevant genetic signatures in a noisy, real-world
dataset of sequences from a rapidly evolving viral pathogen.
The identified amino acid signatures recapitulate and expand
on previously published amino acid variants associated with HAD.
Dunfee et al. 2006 reported that the N283 variant was present at
high frequencies in virus from the brain of HAD patients, and
increases gp120 affinity for CD4, enhancing replication in
macrophages and microglia [71]. HAD signature 2_05 requires
a polar, hydrophilic amino acid at position 283, which includes N,
the most polar amino acid observed in that position in the brain
dataset, as ranked by Atchley Factor I. Non-HAD signature 2_02
requires a V at position 283, the least polar most hydrophobic
amino acid observed at that position in the brain dataset. Power
Figure 8. Validation of HAD signatures against brain-derived env sequences from an independent cohort. A total of 75 brain-derived
sequences from 10 independent patients (x-axis) are visualized as matching or not matching each HAD signature (y-axis). All patients in the
independent cohort were diagnosed with HAD. One sequence has been omitted from patient E21 because phylogenetic mapping from the original
publication indicated it might be a blood-derived contaminant. A second sequence in E21, matching no HAD signatures, was of indeterminate
compartment of origin, and was retained.
doi:10.1371/journal.pone.0049538.g008
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[56]; when converted to HXB2 numbering, these correspond to
positions 308 and 333. At position 308, H was HAD associated,
whereas P was non-HAD associated. Position 308 occurs in HAD
signatures 2_01 and 2_05, in both cases requiring small amino
acids. H is slightly smaller than P by Atchley Factor 3. Signature
2_05 includes H and excludes P, while signature 2_01 includes
both, excluding larger amino acids. Position 333 was not identified
in signatures; however, neighboring position 334 is found in
signature 2_05. Pillai et al. 2006 identified positions 300, 304, 308,
and 314 as associated with CSF versus blood, and S at position
300 in CSF virus associated with HAD [18]. Positions 304 and 308
were each included in several signatures we identified. Position
314 was not included, however, flanking positions 313 and 315
were found across 4 signatures. This also highlights one advantage
to our approach; in addition to identifying positions with clear
amino acid biases, we also identify linked sets of positions, only
correlated when considered together.
Examination of the observed signatures within the structure of
the HIV env protein suggests how these amino acids may interact
within the three-dimensional structure of the active protein. The
env V3 region consists of a stem-loop structure formed by amino
acid positions 296 through 330, with positions 312 to 315 forming
the tip of the loop. Most signatures incorporate a central position
at the V3 loop tip flanked by pairs of equidistant positions on the
stem, in agreement with previous work finding that covarying
positions in V3 tend to bridge opposite strands of the V3 loop [19–
21]. Signature 2_01 includes positions 308 and 317, previously
described as linked [19], and signatures 2_03 and 2_05 contain
other nearby positions (307 or 308, paired with 317 or 319). Other
signatures follow a similar structural pattern, in some instances
bridging greater distance between sites. Signature 1_01 includes
positions 304 and 328, and signature 1_04 includes 290 and 343 in
the C2 and C3 regions. Additionally, clusters of several positions
appear to define important regions within the protein linked to
HAD phenotype. Positions 343–344 occur in three HAD
signatures, and positions 307–308 and 317–319 occur in three
HAD signatures. Notably absent are positions in the conserved
base of the V3 loop, (positions 298–303, and 322–327) [96–98],
which is involved in interactions with the CCR5 coreceptor [99].
The amino acid properties required at each position may also
begin to define functional requirements within the protein.
Signatures 2_01 and 2_05 require low molecular size and low
secondary structure at positions 307 and 308, while signature 2_03
requires isoleucine at position 307, which would also satisfy the
size and secondary structure requirements of 2_01 and 2_05.
These signatures also require hydrophobic, nonpolar residues with
high pI and charge at positions 317–319.
Interpreting mechanistic implications of these signatures
requires consideration of viral replication dynamics and how this
Figure 9. Validation of HAD signatures against CSF-derived sequences from an independent cohort. A. Visualization of 393 CSF-derived
sequences from 41 independent patients matching HAD signatures. Conventions are the same as in Figureo ˆ 7. B. Proportion of patients with CSF-
derived sequence matching signature 1_04 and signature 2_03. Conventions are the same as in Figureo ˆ 6. C. Amino acid diversity in sequences
matching signature 1_04 and signature 2_03. Left column: amino acid requirements in the signature. Middle and right column: amino acids observed
in matching sequences from the brain and from CSF.
doi:10.1371/journal.pone.0049538.g009
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high baseline plasma viral load increase the risk of developing
neurocognitive impairment in treatment-naı ¨ve patients [48] and
suppressive HAART is protective, particularly against the more
severe forms of HAD [27,30,34]. Nonetheless, brain atrophy can
be detected by neuroimaging even in patients with well-controlled
viral replication [26]. Though these results suggest an association
with disease progression, HAD appears more closely linked to
other mechanisms including chronic viral replication in the brain
and activation of CNS macrophages and microglia. Previous
reports have shown that HAD is associated with increased viral
genetic compartmentalization in CSF compared to non-CNS
tissues, suggesting that CSF viral sequences are derived from
unique viral populations replicating within the brain [69,73,100].
The signatures we identified may be directly or indirectly related
to these changes in CNS replication dynamics. In the first case,
amino acid changes in the signatures may enhance HIV
interactions with CD4 and/or CCR5, thereby increasing viral
entry and replication in macrophages, viral replication in the
brain, and/or neurotoxicity, possibly via increased immune
activation or activation of chemokine receptors
[58,60,61,66,69,101–106]. Alternatively, signatures linked to
HAD may reflect specific viral adaptations driven by host selection
pressures, such as humoral or cellular immune responses targeting
specific viral epitopes, that may differ between HAD and non-
HAD patients. Further studies are needed to investigate these
potential links between viral genetics and susceptibility to HAD.
Examination of the frequency of the identified signatures across
patients showed that for most signatures, all or nearly all brain-
derived viral sequences from a matching patient matched the
signature. Most patients were sampled at autopsy with late-stage
AIDS, allowing viral mutations conferring a selective advantage to
expand to a majority variant. Further study incorporating
sampling at earlier time points, for example longitudinal CSF
samples with a brain sample obtained at autopsy, would better
describe the dynamics of the emergence of viral genetic signatures
and their role in development of HAD. Examining the pattern of
matching sequences across signatures demonstrated that the
dataset did not contain broadly matching viral sequences
(Figure 7). Instead, we observed that sequences predominantly
matched a small number of signatures, suggesting that the dataset
consists of distinct subpopulations.
The method employed by the PART algorithm, iteratively
generating a signature then removing sequences matching that
signature, additionally has the potential to reveal interesting
substructures within the dataset. In this study, we were interested
in the distribution of signatures across all sequences in the dataset.
However, we also performed a layered analysis by Fisher’s exact
test, mirroring the PART algorithm by sequentially analyzing each
signature and removing each sequence once it matches a signature
(data not shown). By this approach we observed two additional
HAD signatures, 1_08 and 2_09, with p-values ,0.05 (Figure S1).
These two signatures both demonstrated a dramatic shift in patient
distribution between the independent and layered analysis.
Evaluated independently, signature 1_08 was found in 34 HAD
patients and 33 non-HAD patients (39 HAD and 38 non-HAD
patients total), whereas by a layered approach, signature 1_08 is
found in 16 HAD patients and 0 non-HAD patients (17 HAD and
5 non-HAD patients total). HAD signature 1_08 is relatively
promiscuous alone, matching sequences from both HAD and non-
HAD patients. However, the majority of non-HAD sequences
matching 1_08 also match non-HAD signatures 1_02, 1_03, 1_05
and 1_07. When signatures are considered sequentially, removing
sequences matching earlier signatures, the remaining 1_08
matching sequences are uniquely from HAD patients. This
suggests that the amino acid changes in signatures 1_08 and
2_09 may represent a sub-pattern in the dataset, only linked to
HAD in the absence of dominant changes from earlier signatures.
Though further work is required to support these conclusions, this
effect illustrates the power of the PART algorithm to uncover
subsets of structure within the dataset.
We acknowledge some limitations of the study. As with any
machine learning-based work, overfitting (training a classifier on
random noise instead of true features correlated to outcome) is a
concern we sought to address throughout study design. The C4.5
algorithm was selected in part because it incorporates a pruning
step designed to remove overfit decision tree branches. The
genetic relatedness of sequences within a patient was addressed by
weighting individual sequences to normalize patients by sequenc-
ing depth. Finally, leave-one-out cross-validation generating
independent training and testing sets and class-permuted negative
controls were used to test for overfitting. Ideally, a machine
learning analysis would initially divide the dataset into well
balanced training and test sets. In this case, however, though 78
patients represents a dataset of unprecedented size in the field, it
was not of sufficient size to split for data mining, requiring the use
of cross-validation methodologies. We were, however, able to
assemble an independent test set of 10 HAD patients, in which we
validated the predictive power of these signatures.
Application of this pipeline to larger datasets, either from other
viral pathogens or by expanding the number of HIV samples
available, will allow more traditional splitting into training and test
sets and increase the power of the analysis to reveal subtle patterns
in the dataset. We focused our analysis on the C2-V3-C3 region of
env, in part because of its biological relevance, but also because this
region contained the best sequencing coverage. However, our
method is also well suited to analysis of data sets with wider
sequencing. Indeed, the iterative signature generation we utilized
can be applied to identify genetic signatures across a large span of
genetic sequence.
Application of modern sequencing technologies has facilitated
the assembly of large datasets of viral pathogen sequences from
clinical samples. As the depth and power of these datasets expands,
the challenges of analyzing clinically-derived data from rapidly
evolving viral pathogens across multiple hosts also increases. To
fully utilize these datasets, it is imperative to design analysis
techniques that can address these challenges in an efficient and
robust manner. We developed a technique that uses validated data
mining tools that give us the flexibility and power to increase the
dimensionality of our analysis and mine the biochemical properties
represented by amino acid identities. This method represents a
significant advance in the ability to identify clinically important
genetic signatures from sequence data sets. Its application to a
variety of viral pathogens will lead to greater understanding of
host-pathogen interactions. Applying this technique to HIV env
sequences from the brain allowed us to identify genetic signatures
correlated with the development of HAD. Examining the amino
acid and biochemical requirements of these signatures will inform
further investigations into mechanisms driving the development of
HAD, with the goal of developing better diagnosis tools and
treatment regimens. Further development and application of this
analysis pipeline also has broader applications for the identification
of genetic signatures linked to clinical outcome in other viral
pathogens.
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Figure S1 Amino acid identity and biochemical factor
requirements for HAD and non-HAD associated signa-
tures. Amino acid requirements at each position in HAD and
non-HAD associated signatures are plotted. For each ‘‘position:
factor’’ pair, all amino acids are plotted at their value for that
factor. Amino acids observed at that position within the brain-
derived dataset are plotted in black, while those not observed are
gray. The B-clade consensus amino acid is plotted in large font.
The colored bar indicates the range of acceptable values in that
signature. Lower range ends are open, indicated by a dotted line,
(signature 1_01, position 328 excludes Q). Upper range ends are
closed, indicated by a solid line (signature 2_03, position 321
includes S).
(PDF)
Figure S2 Proportion of sequences per patient from the
brain training dataset matching HAD and non-HAD
signatures. For each signature, HAD (red) and non-HAD (blue)
patients are plotted according to their total number of sequences
(x-axis) and number of sequences matching the signature (y-axis).
Patients with no matching sequences are omitted from the plot for
clarity, but are included for statistical calculations. Dashed line
indicates slope=1 at which all sequences in a patient match
signature. Jitter has been added to visualize overlapping points.
Text indicates p-value by Fisher’s exact test and the number of
patients from each class with matching sequences.
(PDF)
Table S1 Patient details for the brain training, brain validation,
and CSF validation HIV env sequence datasets. All annotations are
drawn from the original publication, or from the HIV Brain
Sequence Database, which drew annotations from the original
publication. Blanks indicate data not available.
(XLSX)
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